Therefore, platelet-targeted FXa gene therapy holds significant promise as an ideal alternative treatment for hemophilia patients, especially those who have developed anti-FVIII or anti-FIX inhibitors following replacement therapy. This evidence concerns the gene F8 and hemophilia.